RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Hypoplastic Left Heart Syndrome: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Human iPSC-Derived Cardiomyocytes Maladaptively Remodel to Cyclic Stretch in Hypoplastic Left Heart Syndrome
Verma RS et al. (17 October 2026)
https://doi.org/10.64898/2026.10.11.758388
- 2.
A New HOPE for Hypoplastic Left Heart Syndrome: Technique for Primary En-Bloc Heart and Aorta Transplant with Hypothermic Oxygenated Recovery of a DCD Heart.
Thomassen Maja Brøgger et al., The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42887611/
- 3.
Assessment of Atrioventricular and Ventriculoarterial Coupling Indices in Patients with Hypoplastic Left Heart Syndrome Utilizing Cardiac MRI and Invasive Hemodynamics
Reid AJ et al. (14 October 2026)
https://doi.org/10.21203/rs.3.rs-11089318/v1
- 4.
Outcomes of the Rapid Two-Stage Norwood Procedure in Hypoplastic Left Heart Syndrome: A Retrospective Cohort Study Stratified by Birth Weight.
Ishida Shinichi et al., Heart, lung & circulation (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42463400/
- 5.
The Norwood procedure in hypoplastic left heart syndrome with dextrocardia and situs solitus: Challenges that can be accepted.
Said Sameh M et al., JTCVS techniques (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42891332/
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Safety of Autologous Cord Blood Cells in HLHS Patients During Norwood Heart Surgery
NCT03431480 · Completed · Phase 1 · Murdoch Childrens Research Institute
Ages 2 Days to 4 Days
https://clinicaltrials.gov/study/NCT03431480
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Hypoplastic Left Heart Syndrome
Hypoplastic left heart syndrome is a rare heart condition present from birth, in which the left side of the heart is underdeveloped and cannot pump blood effectively to the body. It is usually diagnosed before birth or soon after. Treatment involves a series of heart surgeries in early childhood, or sometimes a heart transplant, followed by lifelong cardiac care.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
<h4>Background: </h4> Hypoplastic Left Heart Syndrome (HLHS) is a severe congenital heart defect characterized by underdevelopment of left-sided cardiac structures, requiring staged surgical palliation that establishes the right ventricle as the single ventricle maintaining systemic circulation. After surgery, patients remain highly susceptible to heart failure, possibly due to the increased hemodynamic load imposed on the single surviving ventricle. Because the etiology of HLHS remains poorly understood, elucidating the mechanisms that drive ventricular dysfunction requires model systems that capture both patient-specific genetics and the dynamic mechanical environment of the ventricle. Thus, our objective was to compare how induced pluripotent stem cell (iPSC)-derived cardiomyocytes (iPSC-CMs) from patients with HLHS differ from control in static culture and in response to cyclic stretch. <h4>Methods:</h4> Control iPSCs from two unaffected donors and iPSCs from four HLHS patients were differentiated into iPSC-CMs, engineered into aligned tissues, and cultured statically or exposed to cyclic 20% uniaxial stretch at 1 Hz for 48h. Sarcomere organization was quantified in static tissues using images of immunostained α-actinin. Calcium transients at 1 Hz pacing frequency in static and stretched tissues were evaluated using Fluo-4 calcium indicator dye. Bulk RNA sequencing was performed to evaluate stretch-induced transcriptomic changes in control and HLHS iPSC-CMs. <h4>Results:</h4> In static culture, HLHS iPSC-CMs had modest defects in sarcomere organization and calcium transient morphology compared to control. In response to cyclic stretch, control iPSC-CMs exhibited calcium transients with quicker rise time, a response observed in only one of four lines of HLHS iPSC-CMs. Transcriptomic analysis revealed that all four lines of HLHS iPSC-CMs failed to upregulate calcium handling and sarcomere-associated genes in response to stretch, unlike control iPSC-CMs. Stretch also induced HLHS iPSC-CMs to exhibit pronounced activation of inflammatory signaling pathways, a response not observed in control iPSC-CMs. <h4>Conclusions:</h4> iPSC-CMs from HLHS patients demonstrate aberrant responses to cyclic stretch, including blunted adaptation of calcium transients and heightened inflammatory signaling. These findings implicate defective mechanoadaptation as a potential contributor to single ventricle failure and identify potential candidate biomarkers and new opportunities for therapeutic interventions for HLHS patients.
Common Questions
What is Hypoplastic Left Heart Syndrome?
Hypoplastic left heart syndrome is a rare heart condition present from birth, in which the left side of the heart is underdeveloped and cannot pump blood effectively to the body. It is usually diagnosed before birth or soon after. Treatment involves a series of heart surgeries in early childhood, or sometimes a heart transplant, followed by lifelong cardiac care.
How many clinical trials are available for Hypoplastic Left Heart Syndrome?
RareWays currently indexes 38 clinical trials for Hypoplastic Left Heart Syndrome, of which 2 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Hypoplastic Left Heart Syndrome come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Hypoplastic Left Heart Syndrome.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.